The use of Albumin NPs has attracted considerable attention especially with the approval of Abraxane ® . However, several challenges need to be overcome to maximize their application and effectiveness in clinical settings. The biocompatibility and nonimmunogenic nature of albumin are significant advantages, yet its combination with therapeutic agents can induce protein conformational changes, raising concerns about increased immunogenicity. (29) Moreover, the stability of albumin NPs in biological conditions, while inherently robust, often requires the use of cross-linkers to ensure sustained system stability and facilitate controlled drug release . The toxicity associated with traditional crosslinkers, like glutaraldehyde, along with their potential to interfere with drug efficacy and induced protein denaturation, has prompted the exploration of natural cross-linkers such as glucose and tannic acid.